Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
Nexalin Technology (Nasdaq: NXL, NXLIW) announced it will participate in the 2025 Maxim Growth Summit on October 22, 2025 at The Hard Rock Hotel NYC.
Management will meet attendees to discuss Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™), described as a non-invasive, drug-free, clinically proven neurostimulation therapy the company says has potential to scale worldwide.
The announcement highlights investor and public engagement opportunities at the conference and provides registration details for the Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL, NXLIW) ha annunciato che parteciperà al Maxim Growth Summit 2025 il 22 ottobre 2025 all'Hard Rock Hotel NYC.
La direzione incontrerà i partecipanti per discutere la stimolazione neurofisiologica Deep Intracranial Frequency Stimulation (DIFS™) di Nexalin, descritta come una terapia di neurostimolazione non invasiva, priva di farmaci e clinicamente dimostrata che l'azienda afferma avere potenziale per essere scalata a livello mondiale.
L'annuncio mette in evidenza le opportunità di coinvolgimento per investitori e pubblico durante la conferenza e fornisce i dettagli per l'iscrizione al Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL, NXLIW) anunció que participará en el Maxim Growth Summit 2025 el 22 de octubre de 2025 en The Hard Rock Hotel NYC.
La dirección se reunirá con los asistentes para discutir la Deep Intracranial Frequency Stimulation (DIFS™) patentada de Nexalin, descrita como una terapia de neuroestimulación no invasiva, libre de fármacos y clínicamente probada que la empresa afirma tiene potencial para escalar a nivel mundial.
El anuncio destaca las oportunidades de participación de inversores y del público en la conferencia y proporciona los detalles de registro para el Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL, NXLIW) 는 2025 Maxim Growth Summit에 2025년 10월 22일 뉴욕 Hard Rock Hotel에서 참가한다고 발표했습니다.
경영진은 참석자들을 만나 Nexalin의 독자적인 심_intracranial Frequency Stimulation (DIFS™)를 논의할 예정이며, 이는 비침습적이고 약물 없이 임상적으로 입증된 신경자극 치료로 회사는 전 세계적으로 확장될 가능성이 있다고 말합니다.
발표는 컨퍼런스에서의 투자자 및 대중 참여 기회를 강조하고 Maxim Growth Summit 등록 정보를 제공합니다.
Nexalin Technology (Nasdaq: NXL, NXLIW) a annoncé qu'elle participera au Maxim Growth Summit 2025 le 22 octobre 2025 à The Hard Rock Hotel NYC.
La direction rencontrera les participants pour discuter de la Deep Intracranial Frequency Stimulation (DIFS™) propriétaire de Nexalin, décrite comme une thérapie de neurostimulation non invasive, sans médicament et cliniquement prouvée que l'entreprise affirme avoir le potentiel de déployer à l'échelle mondiale.
L'annonce met en évidence les opportunités d'engagement des investisseurs et du public lors de la conférence et fournit les détails d'inscription au Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL, NXLIW) kündigt an, dass sie am 2025 Maxim Growth Summit am 22. Oktober 2025 im The Hard Rock Hotel NYC teilnehmen wird.
Das Management wird sich mit den Teilnehmern treffen, um Nexalins proprietäre Deep Intracranial Frequency Stimulation (DIFS™) zu diskutieren, die als nicht-invasiv, medikamentenfrei und klinisch erwiesene Neurostimulationstherapie beschrieben wird und laut dem Unternehmen das Potenzial hat, weltweit skaliert zu werden.
Die Ankündigung hebt Möglichkeiten der Investoren- und Öffentlichkeitseinbindung auf der Konferenz hervor und gibt Registrierungsdetails für den Maxim Growth Summit an.
Nexalin Technology (Nasdaq: NXL, NXLIW) أعلنت أنها ستشارك في Maxim Growth Summit 2025 في 22 أكتوبر 2025 في فندق The Hard Rock NYC.
ستلتقي الإدارة بالحضور لمناقشة Deep Intracranial Frequency Stimulation (DIFS™) الملكية للشركة، التي توصف بأنها علاج Neurostimulation غير جراحي وخالٍ من الأدوية ومثبت سريريًا وتقول الشركة إنه يمتلك إمكانات للتوسع عالميًا.
تبرز الإعلانات فرص المشاركة للمستثمرين والجمهور في المؤتمر وتوفر تفاصيل التسجيل لـ Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL, NXLIW) 公告将参与 2025 Maxim Growth Summit，于 2025年10月22日 在纽约市 Hard Rock Hotel 举行。
管理层将与与会者会面，讨论 Nexalin 的专有技术 Deep Intracranial Frequency Stimulation (DIFS™)，被描述为一种 非侵入性、无需药物、临床证明有效的神经刺激治疗，公司表示具有在全球范围扩张的潜力。
公告强调在大会上的投资者与公众参与机会，并提供 Maxim Growth Summit 的注册细节。
- None.
- None.
HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries.
Attendees will have the opportunity to engage with Nexalin’s management team and learn about its proprietary, non-invasive neurostimulation — a drug-free, clinically proven treatment with the potential to scale worldwide.
For additional information about the Maxim Growth Summit, or to register for the event, please click here.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
When will Nexalin (NXL) present at the 2025 Maxim Growth Summit?
How can investors meet Nexalin management at the Maxim Growth Summit?
What technology will Nexalin (NXL) discuss at the conference?
Does Nexalin’s announcement include new financial or clinical data for NXL?
Where and how can I register to attend Nexalin’s Maxim Growth Summit presentation?
